In FL and DLBCL patients, CD46, CD55, CD59, CFH, CFHR1, and CFHR5 gene expression likely affects the clinical response and duration of response to RTX therapy (90). The gene discussed is CFHR5; the disease is diffuse large B-cell lymphoma.